TrialBreast cancer research and treatment2022

Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.

Fangchao Zheng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.